Hence, targeting the PRC1/2 complex (Levy et al., 2022) might force cells to exit diapause-like quiescence in the normal, as well as the cancer, state, guiding CSCs to a proliferative stage amenable to conventional chemotherapies. The gene discussed is PRC1; the disease is cancer.